Literature DB >> 24854988

ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant.

L Falchi1, M Mehrotra2, K J Newberry1, L M Lyle1, G Lu2, K P Patel2, R Luthra2, U Popat3, S Verstovsek1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24854988      PMCID： PMC4824944          DOI： 10.1038/leu.2014.168

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

1.  Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene.

Authors:  O Rosnet; M G Matteï; S Marchetto; D Birnbaum
Journal:  Genomics       Date:  1991-02       Impact factor: 5.736

2.  A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations.

Authors:  W Matthews; C T Jordan; G W Wiegand; D Pardoll; I R Lemischka
Journal:  Cell       Date:  1991-06-28       Impact factor: 41.582

3.  The juxtamembrane domain in ETV6/FLT3 is critical for PIM-1 up-regulation and cell proliferation.

Authors:  Hoang Anh Vu; Phan Thi Xinh; Yasuhiko Kano; Katsushi Tokunaga; Yuko Sato
Journal:  Biochem Biophys Res Commun       Date:  2009-04-05       Impact factor: 3.575

Review 4.  ETV6 fusion genes in hematological malignancies: a review.

Authors:  Etienne De Braekeleer; Nathalie Douet-Guilbert; Frédéric Morel; Marie-Josée Le Bris; Audrey Basinko; Marc De Braekeleer
Journal:  Leuk Res       Date:  2012-05-12       Impact factor: 3.156

Review 5.  Successful allogeneic stem cell transplantation with long-term remission of ETV6/FLT3-positive myeloid/lymphoid neoplasm with eosinophilia.

Authors:  Kazuhisa Chonabayashi; Masakatsu Hishizawa; Masashi Matsui; Tadakazu Kondo; Tatsuharu Ohno; Takayuki Ishikawa; Akifumi Takaori-Kondo
Journal:  Ann Hematol       Date:  2013-07-20       Impact factor: 3.673

6.  Direct binding of Grb2 has an important role in the development of myeloproliferative disease induced by ETV6/FLT3.

Authors:  K Chonabayashi; M Hishizawa; S Kawamata; Y Nagai; T Ohno; T Ishikawa; T Uchiyama; A Takaori-Kondo
Journal:  Leukemia       Date:  2012-11-20       Impact factor: 11.528

7.  Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.

Authors:  Christoph Walz; Philipp Erben; Michael Ritter; Adrian Bloor; Georgia Metzgeroth; Nick Telford; Claudia Haferlach; Torsten Haferlach; Stefan Gesk; Joannah Score; Wolf-Karsten Hofmann; Andreas Hochhaus; Nicholas C P Cross; Andreas Reiter
Journal:  Blood       Date:  2011-06-24       Impact factor: 22.113

8.  FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation.

Authors:  H A Vu; P T Xinh; M Masuda; T Motoji; A Toyoda; Y Sakaki; K Tokunaga; Y Sato
Journal:  Leukemia       Date:  2006-06-08       Impact factor: 11.528

9.  B acute lymphoblastic leukemia with t(14;19)(q32;p13.1) involving IGH/EPOR: a clinically aggressive subset of disease.

Authors:  Jesse M Jaso; C Cameron Yin; Victoria W Lu; Ming Zhao; Lynne V Abruzzo; M James You; Yaling Yang; Raja Luthra; L Jeffrey Medeiros; Gary Lu
Journal:  Mod Pathol       Date:  2013-09-13       Impact factor: 7.842

Review 10.  The role of FLT3 in haematopoietic malignancies.

Authors:  Derek L Stirewalt; Jerald P Radich
Journal:  Nat Rev Cancer       Date:  2003-09       Impact factor: 60.716
  10 in total
  5 in total

Review 1.  Eosinophilia in Hematologic Disorders.

Authors:  Lorenzo Falchi; Srdan Verstovsek
Journal:  Immunol Allergy Clin North Am       Date:  2015-08       Impact factor: 3.479

2.  ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMML.

Authors:  Barbara Spitzer; Filemon S Dela Cruz; Glorymar D Ibanez Sanchez; Yanming Zhang; Wenbin Xiao; Ryma Benayed; Alina Markova; M Irene Rodriguez-Sanchez; Nancy Bouvier; Mikhail Roshal; Andrew L Kung; Neerav Shukla
Journal:  Blood Adv       Date:  2021-04-13

Review 3.  Updates on eosinophilic disorders.

Authors:  Alexandar Tzankov; Kaaren K Reichard; Robert P Hasserjian; Daniel A Arber; Attilio Orazi; Sa A Wang
Journal:  Virchows Arch       Date:  2022-09-07       Impact factor: 4.535

4.  Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.

Authors:  Hengyu Lu; Nicole Villafane; Turgut Dogruluk; Caitlin L Grzeskowiak; Kathleen Kong; Yiu Huen Tsang; Oksana Zagorodna; Angeliki Pantazi; Lixing Yang; Nicholas J Neill; Young Won Kim; Chad J Creighton; Roel G Verhaak; Gordon B Mills; Peter J Park; Raju Kucherlapati; Kenneth L Scott
Journal:  Cancer Res       Date:  2017-05-16       Impact factor: 12.701

5.  A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid/lymphoid neoplasms with eosinophilia and rearrangement of FLT3?

Authors:  E Troadec; S Dobbelstein; P Bertrand; N Faumont; F Trimoreau; M Touati; J Chauzeix; B Petit; D Bordessoule; J Feuillard; C Bastard; N Gachard
Journal:  Leukemia       Date:  2016-10-31       Impact factor: 11.528
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.